Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-002 added to atorvastatin in acute coronary syndrome
NL-OMON34504Phase 3Not yet recruiting
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- Oct 2010
- Modality
- Small Molecules, AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial in acute coronary syndrome (ACS), coronary arteriosclerosis, myocardial infarction (MI) and 1 more comparing A-002 plus atorvastatin with Placebo plus atorvastatin (2 arms). Primary endpoint: First occurrence of major cardiovascular composite endpoint. Planned start Oct 2010; status: not yet recruiting.
02
Drugs
entacingene turiparvovecatorvastatin
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosismyocardial infarction (MI)unstable angina
Beyond the preview
Go deeper on NL-OMON34504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34504.